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Background: The majority of HIV-infected individuals requiring antiretroviral therapy (ART) in Russia are Injection
Drug Users (IDU). Substitution therapy used as part of a comprehensive harm reduction program is unavailable in
Russia. Past data shows that only 16% of IDU receiving substance abuse treatment completed the course without
relapse, and only 40% of IDU on ART remained on treatment at 6 months. Our goal was to determine if it was
feasible to improve these historic outcomes by adding intensive case management (ICM) to the substance abuse
and ART treatment programs for IDU.
Methods: IDU starting ART and able to involve a “supporter” who would assist in their treatment plan were
enrolled. ICM included opiate detoxification, bi-monthly contact and counseling with the case, weekly group
sessions, monthly contact with the “supporter” and home visits as needed. Full follow- up (FFU) was 8 months.
Stata v10 (College Station, TX) was used for all analysis. Descriptive statistics were calculated for all baseline
demographic variables, baseline and follow-up CD4 count, and viral load. Median baseline and follow-up CD4
counts and RNA levels were compared using the Kruskal-Wallis test. The proportion of participants with RNA <
1000 copies mL at baseline and follow-up was compared using Fisher’s Exact test. McNemar’s test for paired
proportions was used to compare the change in proportion of participants with RNA < 1000 copies mL from
baseline to follow-up.
Results: Between November 2007 and December 2008, 60 IDU were enrolled. 34 (56.7%) were male. 54/60
(90.0%) remained in FFU. Overall, 31/60 (52%) were active IDU at enrollment and 27 (45%) were active at their
last follow-up visit. 40/60 (66.7%) attended all of their ART clinic visits, 13/60 (21.7%) missed one or more visit
but remained on ART, and 7/60 (11.7%) stopped ART before the end of FFU. Overall, 39/53 (74%) had a final
6–8 month HIV RNA viral load (VL) < 1000 copies/mL.
Conclusions: Despite no substitution therapy to assist IDU in substance abuse and ART treatment programs,
ICM was feasible, and the retention and adherence of IDU on ART in St. Petersburg could be greatly enhanced
by adding ICM to the existing treatment programs.
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Political, economic, and social changes accompanying the
fall of the Soviet Union in the 1990’s contributed to the es-
tablishment of opium-based drug trafficking routes from
Afghanistan through Russia and a rapid increase in injec-
tion drug abuse rates [1]. Russia currently has one of the
highest rates of injecting drug users (IDU) in the world at
1.8% among adults over 15 years of age [2] and it is esti-
mated that one of the highest IDU populations in the
world (> 80,000 active IDU) live in St. Petersburg, the sec-
ond largest city in Russia [3]. Unsafe injection drug prac-
tices drive the HIV epidemic in Russia, including St.
Petersburg; 76% of incident HIV cases were associated
with unsafe injection practices [4]. In addition, among
HIV infected women who have never injected drugs, al-
most half have had sex with an IDU [5]. HIV prevalence
and incidence rates among IDU in St. Petersburg have
been consistently high, with a 30% prevalence and an inci-
dence of 4.5 per 100 person-years in 2003 [6,7], 14 per
100 person-years incidence in 2008 [8], and 35% preva-
lence and 7.2 per 100 person-years incidence in 2010 [9].
Few IDU in Russia are currently receiving anti-retroviral
treatment (ART). Almost 90% of all people with HIV in
Russia are IDU but only 6% on ART are IDU [10]. One of
the main obstacles to drug abuse and HIV treatment of
active IDU is the low adherence and retention rates. Only
16% of IDU who attended substance abuse treatment pro-
grams completed the entire course without relapse [11].
In Russian the following components are available as
substance abuse treatment: short-term intensive de-
toxification, opiate antagonist treatment (naltrexone),
psychotherapy and social rehabilitation. The majority
of IDU in St.Petersburg have access only to short-term
detoxification, counseling with psychotherapy ele-
ments and social rehabilitation programs based on the
12-step model. Although HIV care and ART are cur-
rently available free for all HIV-infected individuals
according to WHO guidelines for starting ART, self re-
port and cross-sectional studies suggest IDU are not
only less likely to access ART, they are less likely to be
retained in care: only 40% of IDU on ART remain on
treatment at 6 months [12]. Thus clinicians remain reluc-
tant to treat IDUs because they fear low retention and ad-
herence [13]. There is currently no effective system of case
management for persons on ART in Russia.
Adherence to ART is critical to the effective treatment of
HIV/AIDS. Adherence to prescribed doses may need to be
as high as 90%-95% to achieve suppression of viral replica-
tion and prevent the development of resistant viral variants
[14]. Active substance abuse has been associated with a de-
creased adherence to ART [15-17]. However, former users
or those in substance abuse therapy programs have com-
parable adherence to those that never used [18]. IDU status
itself is not a barrier to treat HIV. A meta-analysis of 12studies (>9000 patients) found no difference in ART resist-
ance rates among IDU (23% of sample) and non-IDU [19].
Case management is an effective strategy for HIV
infected IDU patients to improve substance abuse and HIV
treatment outcomes [20,21]. HIV-infected individuals with
case managers are more likely to receive benefits advocacy,
psychological services, and emotional and practical sup-
port. HIV case management is associated with increased
utilization of support services and a decrease in unmet
needs [22,23]. A brief, focused case management system in
U.S. urban centers helped newly diagnosed HIV-positive
individuals successfully access HIV care [24]. Among HIV-
infected homeless and marginally-housed individuals, case
management was associated with improved self-reported
antiretroviral adherence and increased CD4 cell count [25].
A system of case-management of HIV-infected IDU in
Brazil was widely acceptable to health care professionals in-
volved in the medical care of IDU and peer-based support
groups contributed to increased ART adherence [26]. In
Lesotho a nurse-initiated managed care system resulted in
a retention in care rate of 80% at 12 months and 77% at
24 months [27], and case management has resulted in ad-
herence of greater than 80% in Mozambique and Brazil
[28,29]. The inclusion of informal social networks, commu-
nity support and relatives or friends in care is shown to be
beneficial [30-32].
A prospective cohort study of HIV uninfected IDUs at
risk for HIV-infection in St. Petersburg (DAIDS HPTN
033) demonstrated the effectiveness of a case management
model in retention of IDU to long-term follow-up [6,7].
This study obtained 80% retention, and when adjusted for
non-controlled reasons, such as incarceration or death,
the retention rate was 90%. This clearly demonstrates the
potential for intensive case management (ICM) to im-
prove retention among active IDUs. We sought to exam-
ine the feasibility of ICM to improve substance abuse and
HIV treatment outcomes for IDU in Russia.
Methods
Study population, inclusion criteria
HIV-infected, active IDU (within the last 6 months),
who were eligible to start ART or recently began ART
(within the last 3 month); were able to identify a parent,
relative, partner or friend (supporter) who could actively
assist them in their treatment plans; and for the active
users, were willing to enroll in a 10 day in-patient de-
toxification program, were recruited at the City AIDS
Center, St. Petersburg, Russia and invited to participate
in the feasibility study.
Study visits
Once an IDU was confirmed eligible, an enrollment visit
was conducted which included an informed consent pro-
cedure, a risk assessment questionnaire including drug
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havior evaluation, a physical examination of the skin
looking for fresh needle marks, a urine drug screen and
an alcohol breathalyzer. Enrollment also included a base-
line CD4 count and HIV RNA viral load result extracted
from the patients HIV care chart. If the participant was
not currently on ART, ART began within 30 days of the
enrollment visit. In addition, the IDU provided detailed
locator information for themselves and their identified
supporter.
Each participant was assigned to a personal case manage-
ment team: a social worker and psychologist who both were
responsible for the patient’s follow-up and the development
and implementation of their individual case management
plan. Phone contacts or home visits were conducted by
case managers when any ART clinic appointment was
scheduled or missed. Any scheduled appointment was con-
sidered a missed visit after one week without re-scheduling
through communication between the case manager or City
AIDS Center staff and the patient. The case managers also
communicated monthly with the patient supporter or more
frequently during any crisis period or to assist with a sched-
uled or missed appointment.
Follow-up study visits occurred every 2 weeks for the
8 months of study duration. The full follow-up period was
determined per protocol and was set at 8 months due to
budget restrictions. Each follow-up visit included an inter-
view on recent behavior including drug use, self reported
adherence to their ART regimen, social harms, a physical
exam looking for fresh needle marks, and a urine drug test.
Also during each follow-up visit participants received indi-
vidual drug and ART counseling. ART clinic appointment
schedules (and ART distribution) were variable, depended
on the clinician, and ranged from every one month to every
three months. During visits at 4 and 8 months the HIV risk
behavior and psychological behavior questionnaire was
repeated.
Outcomes
Retention was stratified into three categories based on
how many months of ART each participant received: 1.
attended all clinic appointments including the 8 month
follow-up visit; 2. attended some but not all clinic appoint-
ments, including the 8 month follow-up visit; 3. stopped
ART before the 8 month follow-up period was complete.
Adherence was determined by the final HIV RNA result
that occurred between their 6–8 month follow-up visit.
HIV viral load was quantified using Roche RNA PCR
1.5 with a lower limit of detection of 50 copies/mL. CD4
was quantified using FACS count, both conducted as the
standard of care at the City AIDS Center.
Drug abuse relapse was considered three consecutive
days of drug use after a negative urine drug screen and
was determined by self-report, history provided by thesupporter, clinical examination for the presence/absence
of fresh puncture marks and additional urine drug tests.
Case management was continued regardless of drug
use status.
Analysis
Descriptive statistics were calculated for all baseline demo-
graphic variables, baseline and follow-up CD4 count, and
viral load. Median baseline and follow-up CD4 counts and
RNA levels were compared using the Kruskal-Wallis test.
The proportion of participants with RNA< 1000 copies
mL at baseline and follow-up was compared using Fisher’s
Exact test. McNemar’s test for paired proportions was
used to compare the change in proportion of participants
with RNA < 1000 from baseline to follow-up. Stata v10
(College Station, TX) was used for all analysis.
Ethical considerations
This pilot program was conducted in compliance with the
protocol, International Conference on Harmonization Good
Clinical Practice E6 (ICH-GCP) and the applicable regulatory
requirements and the ethical considerations stated in the
declaration of Helsinki. This program was approved by insti-
tutional review boards at the University of North Carolina
and the Biomedical Center in St. Petersburg.Results
Between November 2007 and May 2008, 901 HIV positive
patients at the City AIDS center in St. Petersburg, Russia
were screened for inclusion in the pilot study. Among
them 346 (38.4%) were injection drug users with a history
of active injection in the past 6 months, and 60 (17.3%)
were eligible and consented to participate. The primary
reasons for ineligibility were 171 (49.4%) were not eligible
for ART, 49 (14.2%) refused to attend detoxification and
only 16 (4.6%) had no supporter. Among the 60 enrolled,
34 (56.7%) were male; the median age was 31 years (range
18–41); 46 (76.7%) had at least a secondary education and
only 7 (11.7%) were fully employed. The median age at
first drug injection was 17 years with a median of 10 years
of abuse. The “supporters” were mostly female (51; 85.0%);
a parent (37; 61.7%); or a sexual partner (14; 23.3%).
At enrollment 31/60 (51.7%) were actively injecting.
29/60 (48.3%) had actively injected in the previous
6 month but were drug free at the enrollment date.
Among the 31 actively injecting participants 30 (96.8%)
were injecting heroin, 1 (3.2%) was injecting psycho stimu-
lants, and 21/31 (67.7%) admitted to sharing injection
paraphernalia in the past month. All 31 active users began
a 10-day detoxification program but only 5 (16.1%) com-
pleted the program. However, 26/31 (83.9%) repeated the
detox program at least one additional time during their 8-
month follow-up period.
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to enrollment and 1 months following enrollment. Sixteen
(26.7%) started ART prior to enrollment. The reasons for
ART initiation were 45 (75.0%) CD4 <300 cells/mL; 31
(51.7%) RNA >50,000 copies mL; and 3 (5.0%) an oppor-
tunistic infection. 28/60 (46.7%) were asymptomatic at ini-
tiation. The initial ART regimens included 29 (61.7%)
AZT/3TC/EFV; 7 (14.9%) AZT/3TC/LPV/r; and 4 (8.5%)
DDI/3TC/NVP.
The overall follow-up rate with the case managers at
8 months was 54/60 (90.0%). 40 subjects (66.7%) attended
all of their ART clinic appointments (Group 1); 13 (21.7%)
were partially compliant to their ART clinic appointments
(Group 2), including 6/13 (46%) who attended at least 90%
of their clinic appointments; and 7 (11.7%) stopped at-
tending their appointments (and receiving ART) on their
own prior to the end of the 8 month follow-up period
(Group 3) (Table 1). There was no statistically significant
difference between the 3 retention groups according to
gender, age, education, employment or living situation
(data not shown).
The 8 month intensive case management effort in-
cluded a medium number of 15 case manager contacts
per subject, of which 33.4% were unscheduled contacts
and the result of missed appointments or personal cri-
sis. In addition, during the 8 month follow up period
the case managers had a medium of 8 contacts with
each “supporter” of which 18.2% were also unsched-
uled. Group counseling sessions were offered on a
weekly basis. However, only 24/60 (40%) attended at
least one session and the median number of sessions
attended by these 24 was 2. Table 2, and Figures 1 and
2 provide data on the ART initiation and last follow-up
CD4 and RNA result by levels of retention. At initiation
the total median CD4 was 215 cells/mL with the me-
dian among the group who stopped ART at 160 cells/
mL. There was no difference in the median CD4 count
between the three groups at baseline (p = 0.33). There
was a statistically significant improvement in the CD4










40 (66.7%) 5 36
Participants who were
partially adherent to
ART during 8 months




7 (11.7%) 1 21baseline visit for the groups that were completely or
partially adherent, but not for the group that stopped
ART prior to the 8 month visit. The total median viral
load at initiation was 12,000 copies/mL with the me-
dians per adherence group ranging from 5,842 to
341,259 copies/mL with the highest value in the group
that stopped ART early. At the last follow-up visit, the
overall median RNA copies/mL was 64, with a median
range from 50 copies/mL in those who attended all
clinic visits to 3,750 in those who stopped ART prior to
the end of the follow-up (p = 0.04). 84% of the fully ad-
herent group had RNA copies mL <1000; the partially
adherent group had 58% and the group that stopped
ART only 25% (p = 0.02). There was no demographic or
behavioral difference by group between the participants
who provided values to the CD4 and RNA analysis and
those who did not.
Overall, 31/60 (51.7%) were active IDU at enrollment
and 27 (45.0%) were active at their last follow-up visit.
However, among the 29 (48.3%) subjects who were drug
free at enrollment, 7 (24.1%) relapsed and were active
users at their last visit. Overall, 33/60 (55.0%) were drug-
free at the last follow-up visit.
Figure 3 illustrates the IDU status (drug free or ac-
tive) of the subjects at their last follow-up visit strati-
fied by their ART clinic appointment attendance. Being
drug free was associated with better adherence/reten-
tion where 27/40 (67.5%) of the group with 100% clinic
attendance were drug free, 6/13 (46.2%) of the group
that attended most, but not all of their visits were drug
free, and none 0/7 (00.0%) of the group that stopped
ART and their clinic appointments before the end
of the 8 month follow-up period were drug free
(P = 0.002).Discussion
Intensive case management for HIV infected IDU is feas-
ible and can be an effective complement to improve HIV
treatment outcomes, including retention and adherence in
Russia. The majority (90%) of participants enrolled in this
pilot study remained in research follow up until the end of
the 8 month project period and 74% had a viral
load <1000 copies/mL at their last visit. This is a sig-
nificant improvement compared to historic data where
only 40% of IDU starting on ART in St. Petersburg
were retained in care at 6 months, and comparable to
the ART adherence performance in the US where, over
a ten year period, 78% of patients achieved viral sup-
pression 6 months after starting combination ART [33].
Although our feasibility study had a small number of
participants, we have shown that with intensive case
management, IDU who have a social or family support
system can achieve high levels of ART adherence (74%)
Table 2 CD4 and RNA at initiation and at 8 month (or last visit) by levels of ART adherence (N = 60)
Attended all clinic
visits (n = 40)
Attended some clinic visits,
including 8 month visit (n = 13)
Stopped ART before 8 month
visit (n = 7)
Total (n = 60)
CD4 Count
Initiation CD4 Count: n(%) 38 (95%) 13 (100%) 5 (71%) 56 (93%)
Median (IQR) 219 (145,306) 213 (84,323) 160 (124,216) 215 (129,301)
Follow-up CD4 Count: n(%) 38 (95%) 13 (100%) 5 (71%) 56 (93%)
Median (IQR) 316 (194,384) 308 (113,360) 123 (100,253) 293 (154,382)
p = 0.02 p = 0.03 p = 0.5
Viral Load (VL)
Initiation VL: n(%) 35 (88%) 12 (92%) 4 (57%) 51 (85%)
RNA <1000: n(%) 16 (46%) 4 (33%) 1 (25%) 21 (41%)
Median (IQR) 5840 (61,156000) 7440 (114,872779) 341259 (75232,911102) 12000 (75,268000)
Final VL: n(%) 37 (93%) 12 (92%) 4 (57 %) 53 (88%)
RNA <1000: n(%) 31 (84%)* 7 (58%)* 1 (25%)* 39 (74%)
p < 0.001 p = 0.4 p = 1.0
Median (IQR) 50 (50,400)** 275 (50,7022)** 3750 (907,153000)** 64 (50,1030)
*p = 0.02 **p = 0.04.
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stable drug use. Although we limited our enrollment to
IDU who identified a support person to help them with
their treatment program, only 5% of the 346 IDU’s
screened did not have a viable support person. This is
reassuring and consistent with the demographic data
that shows almost all IDU either live at home with
their parents or have a steady sexual partner. Thus, the
strategy of including such a support person in case
















Figure 1 CD4 at Baseline and last follow-up visit. Figure 1
provides data on baseline (ART initiation) and last follow-up CD4
result by levels of retention. At initiation the total median CD4 was
215 cells/mL with the median among the group who stopped ART
at 160 cells/mL. There was no difference in the median CD4 count
between the three groups at baseline (p = 0.33). There was a
statistically significant improvement in the CD4 count at the last
follow-up visit compared to the baseline visit for the groups that
were completely or partially adherent, but not for the group that
stopped ART prior to the 8 month visit.Because no substitution therapy is available in Russia,
the options for substance abuse treatment are limited.
Short-term detoxification is notoriously ineffective and
psychological counseling without replacement therapy
also has an extremely high relapse rate. Naltrexone, an
opioid antagonist reduces relapse in Russia [11,34] but
is very expensive and not available to most injectors, es-
pecially in the public sector. Overall, we observed a
modest reduction in active drug use, however one quar-
ter of IDU who were not actively injecting at enrollmentFigure 2 HIV RNA at last follow-up visit. Figure 2 provides data
on ART initiation and last follow-up viral load by levels of retention.
The total median viral load at initiation was 12,000 copies/mL with
the medians per adherence group ranging from 5,842 to 341,259
copies/mL with the highest value in the group that stopped ART
early. At the last follow-up visit, the overall median RNA copies/mL
was 64, with a median range from 50 copies/mL in those who
attended all clinic visits to 3,750 in those who stopped ART prior to
the end of the follow-up (p = 0.04). 84% of the fully adherent group
had RNA copies mL <1000; the partially adherent group had 58%
and the group that stopped ART only 25% (p = 0.02).
Figure 3 ART adherence and IDU status at last follow-up visit.
Figure 3 illustrates the IDU status (drug free or active) of the subjects
at their last follow-up visit stratified by their ART clinic appointment
attendance. Being drug free was associated with better adherence/
retention where 27/40 (67.5%) of the group with 100% clinic
attendance were drug free, 6/13 (46.2%) of the group that attended
most, but not all of their visits were drug free, and none 0/7 (00.0%)
of the group that stopped ART and their clinic appointments before
the end of the 8 month follow-up period were drug free (P = 0.002).
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addiction in the absence of either substitution therapy or
naltrexone. Indeed, all the participants who were lost to
follow-up or stopped ART before the end of the follow-up
period were actively injecting. Countries where substitution
therapy is not available for opiate dependent HIV-infected
persons requiring ART pose a significant challenge to ef-
fective treatment, mostly due to poor adherence and reten-
tion. Even among our population of injectors who all had
a social support system, intensive case management and
the provision of antiretroviral therapy, there was virtually
no effect on drug use.
The HIV/AIDS epidemic in Russia parallels the epi-
demic of drug use in Russia. The majority of partici-
pants in our cohort began injecting drugs when they
were less than 20 years of age and have now been IDUs
for at least 10 years. Many of this initial cohort of drug
users who are still alive, now require ART. However,
the success of the ART program will be hampered by
continued drug use and no widely accessible and ef-
fective substance abuse treatment program.
A comprehensive, multidisciplinary approach to care
for HIV infected IDU has proven effective in other set-
tings [35-37]. In Brazil, an integrated system of mobile
case management and ART and primary care treatment
at the same location as substance abuse treatment in-
cluding substitution therapy was successfully imp-
lemented [26]. Integrating office-based opioid dependence
treatment in HIV primary care has been promoted as an
effective method to improve treatment for HIV-infected
drug users [38].The limitations of our feasibility study include the
small numbers of IDUs followed, no real- time compari-
son group that limited our ability to determine effect-
iveness, and questions about scaling up such a labor
intensive case management system. Though feasible for
a limited number of IDU, its unlikely that the resources
would be available to scale up such an intensive pro-
gram. A less intensive case management intervention
would be sustainable and scalable. We believe the “sup-
porter” support system could be retained within this
system, but we do not know how fewer case manager
contacts with the case and their supporter would affect
the outcomes. Enhancing the use of cell phone technol-
ogy would be one way to reduce the cost per case
managed.Conclusions
Overall, intensive case management for IDU on ART is
a feasible and promising strategy to enhance substance
abuse and ART treatment in Russia. A case management
system provides both individual and public health op-
portunities for prevention activities. Comprehensive pre-
vention packages that coordinate substance abuse and
HIV prevention strategies using case management as the
cornerstone for HIV positive and HIV negative IDU,
with appropriate replacement therapy, will be essential
to improving substance abuse and HIV outcomes.
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